Report Highlights
The global market for enzyme inhibitors was valued at $104.4 billion in 2010 and reached nearly $104.6 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4 billion by 2016.
Report Scope
The scope of this study encompasses enzyme inhibitors in the pharmaceutical and biotechnology industry. BCC Research analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. Emerging markets for enzyme inhibitors include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.
Analyst Credentials
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
Report Highlights
-
During the forecast period, enzyme-inhibiting drugs are projected to be introduced for new indications including asthma and chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, hepatitis C and intermittent claudication.
-
Recent withdrawals of products in the COX-2 inhibitor class along with recent and future introductions of novel products in other classes will rearrange the market share of categories in the enzyme inhibitor sector. Overall, the market for products included in this report is expected to show an average annual growth rate (AAGR) of approximately 6.7% from 2005 to 2011, increasing from $29.2 billion to $43.1 billion.
-
Of all the inhibitor categories, COX-2 and PDE4 will see increases in revenue share for the period 2005 to 2011. Cox-2 inhibitors' share will grow from 12.7% to 18.9%, while PDE4 inhibitors will increase from zero in 2005 to 3.6% in 2011.
Related Reports
Liver Disease Treatments: The Global Market
In 2009, the global market for drugs used to treat liver disease was worth approximately $12.4 billion. Sales in 2010 decreased and the market did not see much progress, causing overall global sales to remain stagnant at $12.4 billion. Estimated sales in 2011 a projected $12 billion (excluding protease inhibitors). The market is expected to rise at a CAGR of 3.3% and reach nearly $14.2 billion by 2016.
Enzymes in Industrial Applications: Global Markets
The global market for industrial enzymes is estimated at $3.3 billion in 2010. This market is expected to reach $4.4 billion by 2015, a compound annual growth rate (CAGR) of 6% over the 5-year forecast period.
Recent Reports
Artificial Intelligence (AI) in Cancer
The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Induced Pluripotent Stem Cells: Global Markets
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.
Commercial Amino Acids
The global market for commercial amino acids was valued at $30.1 billion in 2023. It is expected to grow from $31.8 billion in 2024 to $42.8 billion by 2029, at a compound annual growth rate (CAGR) of 6.1% from 2024 through 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
CRISPR Technology: Global Markets
The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More